Crescent Biopharma, Inc.
CBIOHealthcare|Biotechnology|US
$13.54
+0.60 (+4.64%)
DCF Value
$20.78
Tangible Book / Share
$5.35
Cash / Share
$5.62
About
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Stock Price
+3.4%(1Y)
1M
-4.1%
3M
-19.6%
6M
-27.8%
YTD
+14.2%
1Y
+3.3%
3Y
-89.9%
5Y
-93.3%
Pipeline Summary
2 total trials2
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2
Active Trials (2)
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497Locally Advanced / Metastatic Solid Tumors
Phase 1Phase 2Recruiting
Enrollment: 540 participants
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07909031Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Phase 1Phase 2Recruiting
Enrollment: 219 participants
Key Facts
Market Cap$502.9M
Employees44 (+1000% YoY)
CEOJoshua T. Brumm
IPO DateJan 10, 2014
Beta1.39
52-Week Range$8.72 – $27.41
Avg Volume351,186
ExchangeNASDAQ
Websitecrescentbiopharma.com
Ownership
Float49.8%
Shares Outstanding37.1M
Recent Insider Trades
Lynch RyanSELL
Sep 16, 2026240 shares @ $17.90
Pinkas JanSELL
Sep 16, 2026658 shares @ $17.90
Im Ellie EunkyungSELL
Sep 16, 2026623 shares @ $17.90
Scalzo Richard WilliamSELL
Sep 16, 2026568 shares @ $17.90
Bispham Barbara HarlinSELL
Sep 16, 2026620 shares @ $17.90
Peers
Recent News
Crescent Biopharma Announces Grants of Inducement Awards
Nov 3, 2026 · globenewswire.com
Crescent Biopharma to Present at November Investor Conferences
Nov 2, 2026 · globenewswire.com
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Reaffirmed as Buy by HC Wainwright
Oct 19, 2026 · defenseworld.net
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Oct 15, 2026 · globenewswire.com
Crescent Biopharma Announces Grants of Inducement Awards
Oct 6, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:01 AM